Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 6/20 | 0.44 |
| ▸ | DPP4 | P27487 | 11/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 8/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 8/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.37 |
| ▸ | FAP | Q12884 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | PREP | P48147 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL343753 | 1.00 | ABCB1 (0.44) | ABCB1DPP4DPP8DPP7DPP9 | |
| SCHEMBL344727 | 0.85 | DPP4 (0.38) | ABCB1DPP4DPP8DPP7DPP9 | |
| SCHEMBL27963865 | 0.84 | DPP4 (0.38) | DPP4DPP8DPP7DPP9FAP | |
| SCHEMBL28070441 | 0.84 | DPP4 (0.38) | DPP4DPP8DPP7DPP9FAP | |
| SCHEMBL542233 | 0.83 | DPP4 (0.39) | DPP4DPP8DPP7DPP9FAP | |
| SCHEMBL343021 | 0.81 | DPP4 (0.51) | DPP4DPP8DPP7DPP9CYP3A4 | |
| SCHEMBL343020 | 0.81 | DPP4 (0.51) | DPP4DPP8DPP7DPP9CYP3A4 | |
| SCHEMBL10022723 | 0.75 | DPP4 (0.36) | DPP4DPP8DPP7DPP9FAP | |
| SCHEMBL27963868 | 0.73 | DPP4 (0.48) | DPP4DPP7 | |
| SCHEMBL17897719 | 0.72 | DPP4 (0.35) | DPP4DPP8DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9249109-B2 | Method for preparing dipeptidyl peptidase-IV inhibitor and intermediate | DONG-A PHARMACEUTICAL CO., LTD. (KR) | 2016-02-02 | — | — | US | disclosed |
| US-20150025241-A1 | METHOD FOR PREPARING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE | DONG-A PHARMACEUTICAL. CO., LTD (KR) | 2015-01-22 | — | — | US | disclosed |
| EP-2415753-B1 | METHOD FOR PREPARING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE | DONG A PHARM CO LTD (KR) | 2014-08-27 | — | — | EP | disclosed |
| EP-2669265-A2 | Improved method for preparing dipeptidyl peptidase-IV inhibitor and intermediate | Dong-A Pharmaceutical Co., Ltd. (KR) | 2013-12-04 | — | — | EP | disclosed |
| US-20120016125-A1 | METHOD FOR PREPARING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE | DONG-A PHARMACEUTICAL. CO., LTD (KR) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025241-A1 | METHOD FOR PREPARING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE | DPP4, DPP3, DPP7 | ABCB1 939/4885DPP4 1/4885DPP8 4/4885 |
| US-20120016125-A1 | METHOD FOR PREPARING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE | DPP4, DPP3, DPP7 | ABCB1 939/4885DPP4 1/4885DPP8 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.